Based on this preliminary screen, we selected gilteritinib for further investigation due to the enhanced combinatorial effect with MTL-CEBPA and since it is the only approved FLT3 inhibitor for relapsed/refractory AML.80 This evidence concerns the gene CEBPA and acute myeloid leukemia.